By conducting next generation sequencing, the study revealed the mutational landscape and the clinical value of DDR gene mutations in predicating tumor metastasis and outcomes to platinum-based chemotherapy and platinum-based chemotherapy/immunotherapy in NSCLC patients without EGFR and ALK alterations. Here, ALK is linked to non-small cell lung carcinoma.